Trial Profile

Randomized, optimal dose finding, Phase II Study of triweekly Abraxane in patients with metastatic breast cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms ABROAD

Most Recent Events

01 Dec 2022 Results of subgroup analysis of Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients assessing influence of single nucleotide polymorphisms (SNPs) on CIPN, using genotype data published in the Acta Medica Okayama
14 Dec 2019 Results assessing patient-reported outcome and health related quality of life in patients with metastatic breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
17 Jul 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com